Quince Therapeutics, Inc. — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/22c5667b-8a9f-4fdf-aee8-0be4ac03b1c0/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-84.0M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-161838 |
| FY 2024 | $-56.8M | 2024-01-01 – 2024-12-31 | evidence 0001193125-26-161838 |
| FY 2023 | $-31.4M | 2023-01-01 – 2023-12-31 | evidence 0001193125-26-161838 |
| FY 2022 | $-51.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-008148 |
| FY 2021 | $-89.9M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002571 |
| FY 2020 | $-76.8M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009867 |
| FY 2019 | $-37.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-011165 |
| FY 2018 | $-12.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-011165 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).